# A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation

> **NCT06808217** · — · ACTIVE_NOT_RECRUITING · sponsor: **Boston Scientific Corporation** · enrollment: 550 (actual)

## Conditions studied

- Atrial Fibrillation
- Pulsed Field Ablation
- FARAPULSE

## Interventions

- **DEVICE:** FARAPULSE Pulsed Field Ablation System

## Key facts

- **NCT ID:** NCT06808217
- **Lead sponsor:** Boston Scientific Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-07-30
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 550 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06808217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06808217, "A Registry on the FARAVIEW Technology of the OPAL HDx Mapping System When Used With the FARAWAVE NAV Ablation Catheter in the Treatment of Atrial Fibrillation". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06808217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*